Document is current
Any future updates will be listed below
-
Authors
Johnson, Kristin https://orcid.org/0000-0002-5099-423X
Ikeda, Debra M.
Andersson, Ingvar
Zackrisson, Sophia
-
Funding
Funding for this research was provided by:
ALF
Swedich Society of Medical Radiology
- License Information
-
More Information
Article History
Received: 21 May 2024
Revised: 16 October 2024
Accepted: 4 November 2024
First Online: 20 December 2024
Compliance with ethical standards
:
: The scientific guarantor of this publication is Sophia Zackrisson.
: The authors of this manuscript declare relationships with the following companies: Kristin Johnson has received a speakers fee from Siemens Healthineers and is a consultant for Spago Nanomedicals AB. Debra M Ikeda is a consultant to Hologic, Inc. and to Whiterabbitt.ai. Ingvar Andersson declares no conflict of interest. Sophia Zackrisson has received speaker’s fees from Siemens Healthineers, Pfizer, and Bayer AG and is a patent owner (US patent no. PCT/EP2014/057372).
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Results from the MBTST (n = 7500–14,848) have been reported in previous publications regarding screening accuracy [, ], tumor characteristics and radiographic appearance [], interval cancer rates [], false positive recalls [, , ], cancer detection rates in following screening rounds [], and density measurements [–]. This study presents non-detected cancers in the MBTST, based on all 14,848 trial participants, in a retrospective review of the images, not previously reported.
:
